San Antonio, TX Clinical Trials Report — July 2026

San Antonio participants should act quickly on studies nearing enrollment deadlines: 51 recruiting trials are expected to close within the next 90 days, including 11 that accept healthy volunteers. San Antonio currently has 986 recruiting trials across 538 research facilities, so people who qualify may have several local options—but closing dates can arrive sooner if enrollment targets are reached.

Closing-soon opportunities include cancer, liver, and healthy-volunteer studies

The largest groups of trials approaching their projected closing windows involve prostate cancer and hepatic impairment, with 4 studies each. Breast cancer and advanced solid tumors account for 3 studies each. Other conditions represented among the closing trials include metastatic solid tumors, non-small cell lung cancer, Parkinson’s disease psychosis, HER2-negative breast cancer, healthy participants, and colorectal cancer.

• Prostate cancer (4 trials)
• Hepatic impairment (4 trials)
• Breast cancer (3 trials)
• Advanced solid tumor (3 trials)
• Metastatic solid tumor (2 trials)
• Non-small cell lung cancer (2 trials)
• Parkinson’s disease psychosis (2 trials)
• HER2-negative breast cancer (2 trials)
• Healthy participants (2 trials)
• Colorectal cancer (2 trials)

There are 11 closing-soon trials that accept healthy volunteers, while 81 healthy-volunteer studies are recruiting in San Antonio overall. Eligibility may depend on age, medications, medical history, laboratory results, and time commitments, so interested volunteers should contact study teams now rather than wait for the listed closing period.

New Phase 2 and Phase 3 studies bring major-sponsor options

San Antonio opened 17 new trials in July, down from 38 in May. Drug studies led the new openings with 12 trials, followed by behavioral and device studies with 2 each. The new-trial list includes obesity, overweight, Graves’ disease, several dental conditions, gastric cancer, and hepatocellular carcinoma.

• NCT07684235 is a Phase 3 Amgen extension study of maridebart cafraglutide for participants with obesity or overweight. The trial plans to enroll 3,200 people and evaluates long-term efficacy, safety, and tolerability after an earlier study.
• NCT07680790 is Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study for previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer. It compares izalontamab brengitecan with osimertinib-based treatment approaches and plans to enroll 850 participants.
• NCT07735637 is AstraZeneca’s Phase 3 DURGA-6 study in newly diagnosed, transplant-eligible multiple myeloma. It compares consolidation treatment with AZD0120 against autologous stem-cell transplantation and expects 750 participants.
• NCT07682896 is a Phase 2 study of YB-101 for Graves’ disease. The study evaluates thyroid effects, safety, tolerability, and how the treatment moves through the body in 232 participants.
• NCT07703878 is a Phase 1 Gilead Sciences study evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of GS-1206 in adults with solid tumors. Planned enrollment is 302 participants.
• NCT07707102, sponsored by The University of Texas Health Science Center at San Antonio, studies training strategies for behavioral-health providers delivering Written Exposure Therapy for posttraumatic stress disorder. The study plans to include 300 participants.

The University of Texas Health Science Center at San Antonio sponsors 6 of the new trials. Industry sponsors account for 11 July openings, while other sponsors account for 6. AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, Evopoint Biosciences, Flare Therapeutics, and Gilead Sciences each appear among the named sponsors.

Where San Antonio has the deepest site access

The University of Texas Health Science Center at San Antonio is the city’s leading research location, with 97 recruiting trials. NEXT Oncology follows with 55, while sites listed as Research Site have 39. These leading locations give patients and volunteers practical starting points for oncology, academic medicine, behavioral health, metabolic conditions, and other specialties.

• University of Texas Health Science Center at San Antonio (97 trials)
• NEXT Oncology (55 trials)
• Research Site (39 trials)
• Children’s Hospital of San Antonio (31 trials)
• Methodist Children’s Hospital of South Texas (24 trials)
• START San Antonio (24 trials)
• The University of Texas Health Science Center at San Antonio (20 trials)
• GSK Investigational Site (14 trials)
• Texas Oncology - San Antonio (13 trials)
• Texas Dermatology and Laser Specialists (13 trials)
• UT Health San Antonio (13 trials)
• Brooke Army Medical Center (11 trials)

People seeking cancer studies may want to begin with NEXT Oncology, START San Antonio, Texas Oncology - San Antonio, and the GSK Investigational Site. Families can look to Children’s Hospital of San Antonio and Methodist Children’s Hospital of South Texas. The city’s academic health center appears under several facility names, so searching each listing may reveal additional studies connected with the same broader institution.

Eligibility and alternatives across Texas

Of the 17 new July trials, 2 accept healthy volunteers. One includes children, one is female-only, and one is male-only. Older adults are included in 17 eligibility listings. These categories are not a substitute for full screening requirements, but they can help people identify studies worth reviewing.

Participants willing to travel can also search nearby Texas cities. Houston has 51 recruiting trials, Dallas has 27, and Austin has 12. Fort Worth, Richardson, Edinburg, Fort Sam Houston, and El Paso also have recruiting options.

New openings have fluctuated over the past several months, reaching 41 in March, 29 in May, and 38 in June before falling to July’s 17. With 51 trials approaching closure and 81 healthy-volunteer studies currently available, San Antonio residents should review eligibility and contact local sites early as the next month’s trial pipeline develops.